Cargando…

Concomitant use of magnesium oxide significantly decreases absorption of levodopa preparations in patients with Parkinson’s disease

INTRODUCTION: Constipation is one of the most frequent non-motor symptoms of Parkinson's disease (PD), and magnesium oxide (MgO) is a frequently used laxative. This study aimed to investigate the effect of concomitant use of MgO on the pharmacokinetics of levodopa preparations in patients with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Miyaue, Noriyuki, Yabe, Hayato, Nagai, Masahiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10656210/ https://www.ncbi.nlm.nih.gov/pubmed/38021340 http://dx.doi.org/10.1016/j.prdoa.2023.100227

Ejemplares similares

Ascorbic acid can alleviate the degradation of levodopa and carbidopa induced by magnesium oxide
por: Miyaue, Noriyuki, et al.
Publicado: (2022)

Serum GDF-15 Levels in Patients with Parkinson’s Disease, Progressive Supranuclear Palsy, and Multiple System Atrophy
por: Miyaue, Noriyuki, et al.
Publicado: (2023)

Polysomnographic and Clinical Parameters before and after Zonisamide Therapy for Parkinson's Disease
por: Miyaue, Noriyuki, et al.
Publicado: (2022)

Using Spontaneous Eye-blink Rates to Predict the Motor Status of Patients with Parkinson's Disease
por: Iwaki, Hirotaka, et al.
Publicado: (2019)

Repetitive brainstem lesions in mitochondrial DNA 11778G>A mutation of Leber hereditary optic neuropathy
por: Miyaue, Noriyuki, et al.
Publicado: (2019)

Refractory Longitudinally Extensive Transverse Myelitis after Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination in a Japanese Man
por: Miyaue, Noriyuki, et al.
Publicado: (2021)

The Eldest Female Case of Myasthenia Gravis with an Unusual Presentation: Aspiration Pneumonia as the Initial Manifestation
por: Masuda, Yuya, et al.
Publicado: (2021)

Pharmacokinetics and safety/efficacy of levodopa pro-drug ONO-2160/carbidopa for Parkinson's disease
por: Nomoto, Masahiro, et al.
Publicado: (2018)

Successful Management of Parkinson's Disease Dyskinesia During Local Anesthesia With Dexmedetomidine
por: Nakajima, Takamichi, et al.
Publicado: (2021)

To restrict or not to restrict? Practical considerations for optimizing dietary protein interactions on levodopa absorption in Parkinson’s disease
por: Rusch, C., et al.
Publicado: (2023)

Gender Differences in Levodopa Pharmacokinetics in Levodopa-Naïve Patients With Parkinson’s Disease
por: Conti, Valeria, et al.
Publicado: (2022)

Continuous levodopa for advanced Parkinson’s disease
por: Lundqvist, Christofer
Publicado: (2007)

Mortality in Levodopa-Treated Parkinson's Disease
por: Morgan, John C., et al.
Publicado: (2014)

Long-term safety and efficacy of adjunctive rasagiline in levodopa-treated Japanese patients with Parkinson’s disease
por: Hattori, Nobutaka, et al.
Publicado: (2019)

Jejunal Infusion of Levodopa–Carbidopa Intestinal Gel Versus Oral Administration of Levodopa–Carbidopa Tablets in Japanese Subjects with Advanced Parkinson’s Disease: Pharmacokinetics and Pilot Efficacy and Safety
por: Othman, Ahmed A., et al.
Publicado: (2015)

Pharmacokinetics of Levodopa before and after Gastrointestinal Resection in Parkinson's Disease
por: Nagayama, Hiroshi, et al.
Publicado: (2015)

Falling After Starting Running in a Case of Myoclonus Epilepsy Associated with Ragged-red Fibers with a 8344A>G mtDNA Mutation
por: Miyaue, Noriyuki, et al.
Publicado: (2018)

Phenotypic Diversity of Myoclonus Epilepsy Associated with Ragged-red Fibers with an 8344A>G mtDNA Mutation
por: Miyaue, Noriyuki, et al.
Publicado: (2019)

Modulation of Habit Formation by Levodopa in Parkinson's Disease
por: Marzinzik, Frank, et al.
Publicado: (2011)

“Cueing” for Levodopa-Induced Dyskinesias in Parkinson’s Disease
por: Schaeffer, Eva, et al.
Publicado: (2016)

Dopamine and Levodopa Prodrugs for the Treatment of Parkinson’s Disease
por: Haddad, Fatma, et al.
Publicado: (2017)

Mechanisms of peripheral levodopa resistance in Parkinson’s disease
por: Beckers, Milan, et al.
Publicado: (2022)

Levodopa-Responsive Benign Tremulous Parkinsonism
por: Kano, Osamu, et al.
Publicado: (2013)

Comparison of Endothelial Progenitor Cells in Parkinson's Disease Patients Treated with Levodopa and Levodopa/COMT Inhibitor
por: Lee, Phil Hyu, et al.
Publicado: (2011)

Amphiregulin blockade decreases the levodopa‐induced dyskinesia in a 6‐hydroxydopamine Parkinson's disease mouse model
por: Kambey, Piniel Alphayo, et al.
Publicado: (2023)

Catalytic Activities of Various Niobium Oxides for Hydrogen Absorption/Desorption Reactions of Magnesium
por: Shinzato, Keita, et al.
Publicado: (2021)

Chloride Intracellular Channel Protein 2 Promotes Microglial Invasion: A Link to Microgliosis in the Parkinson’s Disease Brain
por: Choudhury, Mohammed E., et al.
Publicado: (2022)

Apomorphine and Levodopa Infusion Therapies for Advanced Parkinson’s Disease
por: Antonini, Angelo
Publicado: (2009)

Levodopa-induced dyskinesias in Parkinson’s disease: emerging treatments
por: Bargiotas, Panagiotis, et al.
Publicado: (2013)

Future Scenarios for Levodopa-Induced Dyskinesias in Parkinson’s Disease
por: Cerasa, Antonio, et al.
Publicado: (2015)

Levodopa in Parkinson’s Disease: Current Status and Future Developments
por: Tambasco, Nicola, et al.
Publicado: (2018)

Surgical Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease
por: Krishnan, Syam, et al.
Publicado: (2017)

Modulatory Effects of Levodopa on Cerebellar Connectivity in Parkinson’s Disease
por: Mueller, Karsten, et al.
Publicado: (2018)

Impact of Levodopa in Lung Functions in Patients with Parkinson Disease
por: Tandon, Medha, et al.
Publicado: (2020)

Biphasic Levodopa-Induced Freezing of Gait in Parkinson’s Disease
por: Nonnekes, Jorik, et al.
Publicado: (2020)

Cerebellar connectivity in Parkinson's disease with levodopa‐induced dyskinesia
por: Yoo, Han Soo, et al.
Publicado: (2019)

Effect of Levodopa Initiation on the Gut Microbiota in Parkinson's Disease
por: Palacios, Natalia, et al.
Publicado: (2021)

Impact of Levodopa in Lung Functions in Patients with Parkinson’s Disease
por: Al-Mendalawi, Mahmood D.
Publicado: (2021)

Polymeric nanoparticles for dopamine and levodopa replacement in Parkinson's disease
por: Alabrahim, Obaydah Abd Alkader, et al.
Publicado: (2022)

Successful Utilization of Levodopa in HIV-Induced Parkinsonism
por: Almajali, Mohammad, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_c517npe4qg3p47rj8qfb3q7jqq